Aetna modified CPB 0806 for cabazitaxel (Jevtana), effective January 21, 2026. Here's what billing teams need to do.
Aetna, a CVS Health company, updated its cabazitaxel coverage policy under CPB 0806 Aetna system on January 21, 2026. The update expands prior treatment criteria for metastatic castration-resistant prostate cancer (mCRPC), adding novel hormone therapy as a qualifying prior treatment pathway alongside docetaxel. If your oncology billing team submits claims under J9043 or J9064 for cabazitaxel, this change directly affects your medical necessity documentation requirements.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Cabazitaxel (Jevtana) — CPB 0806 |
| Policy Code | CPB 0806 |
| Change Type | Modified |
| Effective Date | January 21, 2026 |
| Impact Level | High |
| Specialties Affected | Medical Oncology, Urology, Hematology/Oncology, Revenue Cycle |
| Key Action | Update prior authorization documentation to reflect expanded prior treatment criteria, including novel hormone therapy (enzalutamide, abiraterone) as a qualifying pathway |
Aetna Cabazitaxel Coverage Criteria and Medical Necessity Requirements 2026
The core of this Aetna cabazitaxel coverage policy is the medical necessity framework for metastatic castration-resistant prostate cancer. Aetna now recognizes two distinct prior treatment pathways that qualify a patient for cabazitaxel.
Pathway 1: Docetaxel-based prior treatment. Aetna covers cabazitaxel when the member was previously treated with a docetaxel-containing regimen. This includes prior treatment with J9171 (docetaxel, 1 mg IV), J9172 (docetaxel, Ingenus formulation), or J9174 (docetaxel, Beizray formulation). Members who are not candidates for docetaxel or who cannot tolerate it also qualify under this pathway.
Pathway 2: Novel hormone therapy prior treatment. This is where the January 21, 2026 update adds real flexibility. Aetna now explicitly covers cabazitaxel following prior treatment with novel hormone therapies — specifically enzalutamide (Xtandi) or abiraterone (Zytiga). These two agents don't have their own dedicated HCPCS codes in this policy, but related steroid support codes J7509 (methylprednisolone oral, per 4 mg) and J7510 (prednisolone oral, per 5 mg) appear in the code set, which makes sense given abiraterone's co-administration requirements.
The two pathways are structured as "or" criteria — not "and." Your patient needs prior treatment with docetaxel or prior treatment with novel hormone therapy. That's a meaningful distinction for patients who moved directly from androgen deprivation therapy to enzalutamide or abiraterone without ever receiving docetaxel.
Small cell/neuroendocrine prostate cancer also qualifies as a covered indication. Aetna considers cabazitaxel medically necessary for metastatic castration-resistant small cell or neuroendocrine prostate cancer, regardless of prior treatment history. This is a narrower population, but make sure your documentation captures the histologic subtype when applicable.
Aetna Jevtana coverage does not require the member to have failed both pathways. One qualifying prior treatment is enough.
Aetna Cabazitaxel Exclusions and Non-Covered Indications
Aetna's position here is direct: all other indications for cabazitaxel are not medically necessary. Any use outside the two covered mCRPC scenarios and small cell/neuroendocrine prostate cancer is classified as experimental, investigational, or unproven.
This matters for billing teams because the ICD-10 code set in this policy spans a wide range — C00.0 through C96.9 (all neoplasms) with a specific carve-out. The code range includes nearly every malignancy, but only C61 (malignant neoplasm of prostate) and the neuroendocrine/small cell subset will clear medical necessity review for cabazitaxel.
If you're submitting J9043 or J9064 with a diagnosis code outside of prostate cancer, expect a claim denial. Don't let the broad ICD-10 range in the code table mislead you — those codes appear in the policy for exclusion tracking purposes, not as covered indications.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| mCRPC — prior docetaxel-containing regimen | Covered | J9043, J9064, C61 | Includes J9171, J9172, J9174 as evidence of prior treatment |
| mCRPC — intolerant to or not a candidate for docetaxel | Covered | J9043, J9064, C61 | Document intolerance or contraindication in medical record |
| mCRPC — prior novel hormone therapy (enzalutamide or abiraterone) | Covered | J9043, J9064, C61 | New pathway added in January 21, 2026 update |
| Metastatic castration-resistant small cell/neuroendocrine prostate cancer | Covered | J9043, J9064, C61 | No prior treatment requirement stated |
| Continuation of therapy — no unacceptable toxicity, no disease progression | Covered | J9043, J9064, 96413, 96415 | Requires ongoing documentation of response and tolerability |
| All other indications (non-prostate cancers, off-label uses) | Not Covered / Experimental | C00.0–C96.9 (except C61) | Classified as experimental, investigational, or unproven |
Aetna Cabazitaxel Billing Guidelines and Action Items 2026
The January 21, 2026 effective date is already here. If you haven't updated your workflows, do it now.
| # | Action Item |
|---|---|
| 1 | Audit your prior authorization templates. Your PA request documentation should now include a field for prior novel hormone therapy. If a patient received enzalutamide or abiraterone before cabazitaxel, that history must appear in the prior auth submission. Don't assume your team is capturing this — check the templates yourself. |
| 2 | Update charge capture for J9043 and J9064. Both codes — J9043 (injection, cabazitaxel, 1 mg) and J9064 (injection, cabazitaxel, Sandoz biosimilar, 1 mg) — need correct ICD-10 linkage. Pair them only with C61 for standard prostate cancer cases. For small cell/neuroendocrine cases, confirm your ICD-10 coding reflects the specific histology before submitting. |
| 3 | Train your oncology coders on the two-pathway structure. The docetaxel pathway and the novel hormone therapy pathway are both valid, but they require different supporting documentation. Prior docetaxel treatment means the record should reference J9171, J9172, or J9174 claims or clinical notes. Prior hormone therapy means documented use of enzalutamide or abiraterone, with J7509 or J7510 claims in the history if applicable. |
| 4 | Document docetaxel intolerance explicitly. If your patient qualifies because they couldn't tolerate docetaxel, the intolerance must be in the clinical notes — not just implied. "Not a candidate" claims without supporting documentation are easy targets for prior authorization denial and post-payment audit. |
| 5 | Lock down your continuation of therapy documentation process. Cabazitaxel billing guidelines under CPB 0806 require ongoing evidence of response for continuation approvals. At each renewal, your clinical team should document no evidence of disease progression and no unacceptable toxicity. Build this into your infusion visit workflow, not just your PA calendar. |
| 6 | Verify infusion administration coding. Cabazitaxel infusions bill with CPT 96413 (chemotherapy administration, IV infusion, up to one hour) for the initial infusion and CPT 96415 (each additional hour) for extended infusions. Make sure your infusion center is capturing time-based units correctly — undercoding here is a direct reimbursement loss. |
| 7 | Don't use J9043 and J9064 interchangeably without payer guidance. The Sandoz formulation (J9064) is explicitly listed as not therapeutically equivalent to J9043. Substituting one for the other without confirming dispensed product creates claim and audit risk. Bill what was administered. |
If your patient population includes a significant number of mCRPC patients who went straight from novel hormone therapy to cabazitaxel, this policy change materially expands your covered population. That's a positive shift for reimbursement. Talk to your compliance officer before the effective date if you're unsure how to document the novel hormone therapy pathway for patients already mid-treatment.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Cabazitaxel Under CPB 0806
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J9043 | HCPCS | Injection, cabazitaxel, 1 mg |
| J9064 | HCPCS | Injection, cabazitaxel (Sandoz), not therapeutically equivalent to J9043, 1 mg |
Covered CPT Codes (Infusion Administration)
| Code | Type | Description |
|---|---|---|
| 96413 | CPT | Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance |
| 96415 | CPT | Chemotherapy administration, intravenous infusion technique; each additional hour |
Key ICD-10-CM Diagnosis Codes
| Code | Description | Coverage Note |
|---|---|---|
| C61 | Malignant neoplasm of prostate | Primary covered diagnosis for mCRPC indications |
| C00.0–C60.9, C62.00–C96.9 | Neoplasms (except malignant neoplasm of prostate) | Listed in policy — NOT covered for cabazitaxel; do not link J9043 or J9064 to these codes |
Get the Full Picture for CPT 96413
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.